Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
MRK

MRK - Merck & Co Inc Stock Price, Fair Value and News

129.43USD+0.17 (+0.13%)Delayed
Watchlist

Market Summary

USD129.43+0.17
Delayed
0.13%

MRK Alerts

  • 8 major insider sales recently.

MRK Stock Price

View Fullscreen

MRK RSI Chart

MRK Valuation

Market Cap

328.0B

Price/Earnings (Trailing)

71.18

Price/Sales (Trailing)

5.53

EV/EBITDA

38.62

MarketCap/EBT

44.04

MRK Price/Sales (Trailing)

MRK Profitability

EBT Margin

12.56%

Return on Equity

11.17%

Return on Assets

4.32%

MRK Fundamentals

MRK Revenue

Revenue (TTM)

59.3B

Rev. Growth (Yr)

6.7%

Rev. Growth (Qtr)

6.17%

MRK Earnings

Earnings (TTM)

4.6B

Earnings Growth (Yr)

46.09%

Earnings Growth (Qtr)

179.41%

Breaking Down MRK Revenue

Last 7 days

1.9%

Last 30 days

7.7%

Last 90 days

25.6%

Trailing 12 Months

18.5%

How does MRK drawdown profile look like?

MRK Financial Health

Current Ratio

1.38

Debt/Equity

0.82

Debt/Cashflow

0.51

MRK Investor Care

Dividend Yield

2.21%

Dividend/Share (TTM)

2.8

Buy Backs (1Y)

0.05%

Diluted EPS (TTM)

1.8

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202357.9B58.3B59.3B0
202254.0B57.2B59.0B59.3B
202141.0B43.0B45.2B48.7B
202040.4B38.0B36.5B42.4B
201943.1B44.4B46.0B39.1B
201840.7B41.3B41.7B42.3B
201739.9B40.0B39.8B40.1B
201639.4B39.4B39.9B39.8B
201541.4B40.2B39.8B39.5B
201443.6B43.5B43.1B42.2B
201346.2B44.9B44.5B44.0B
201248.2B48.4B47.8B47.3B
201146.1B47.0B47.8B48.0B
201033.5B38.9B44.0B46.0B
200924.6B25.6B27.0B27.4B
200824.1B24.0B23.9B23.9B
200700024.2B

Tracking the Latest Insider Buys and Sells of Merck & Co Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 14, 2024
davis robert m
sold
-10,661,600
125
-85,021
chairman, ceo & president
Feb 14, 2024
davis robert m
acquired
6,268,600
73.73
85,021
chairman, ceo & president
Feb 14, 2024
litchfield caroline
acquired
2,223,940
58.08
38,291
evp & cfo
Feb 14, 2024
litchfield caroline
sold
-4,805,520
125
-38,291
evp & cfo
Feb 13, 2024
romanelli joseph
sold
-124,888
124
-1,000
president, human health int?l
Feb 13, 2024
davis robert m
sold
-18,877,400
125
-150,000
chairman, ceo & president
Feb 13, 2024
davis robert m
acquired
11,127,200
74.1811
150,000
chairman, ceo & president
Feb 09, 2024
li dean y
acquired
912,553
62.07
14,702
executive vp & president, mrl
Feb 09, 2024
li dean y
sold
-1,845,080
125
-14,702
executive vp & president, mrl
Feb 07, 2024
williams david michael
sold
-185,108
127
-1,451
evp,chief info&digital officer

1–10 of 50

Which funds bought or sold MRK recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 22, 2024
SIERRA SUMMIT ADVISORS LLC
new
-
626,211
626,211
0.18%
Feb 22, 2024
Sentry LLC
new
-
6,211,460
6,211,460
1.32%
Feb 22, 2024
Scarborough Advisors, LLC
new
-
442,231
442,231
0.15%
Feb 22, 2024
Dodge & Cox
reduced
-1.74
683,529
17,546,200
0.01%
Feb 22, 2024
AUXIER ASSET MANAGEMENT
reduced
-1.08
607,825
13,387,100
2.17%
Feb 21, 2024
CHELSEA COUNSEL CO
reduced
-13.69
-260,620
2,769,010
1.47%
Feb 21, 2024
Raleigh Capital Management Inc.
reduced
-0.05
73,629
1,334,160
0.62%
Feb 21, 2024
Garde Capital, Inc.
added
25.42
190,000
768,000
0.06%
Feb 21, 2024
WNY Asset Management, LLC
added
5.78
123,058
1,147,000
0.19%
Feb 21, 2024
Novak & Powell Financial Services, Inc.
new
-
482,218
482,218
0.32%

1–10 of 47

Are Funds Buying or Selling MRK?

Are funds buying MRK calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own MRK
No. of Funds

Unveiling Merck & Co Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
9.66%
244,767,034
SC 13G/A
Jan 26, 2024
blackrock inc.
8.0%
201,836,434
SC 13G/A
Feb 09, 2023
vanguard group inc
8.96%
227,205,978
SC 13G/A
Feb 03, 2023
blackrock inc.
8.5%
215,011,385
SC 13G/A
Feb 09, 2022
vanguard group inc
8.36%
211,202,531
SC 13G/A
Feb 01, 2022
blackrock inc.
7.8%
198,224,264
SC 13G/A
Feb 10, 2021
vanguard group inc
8.24%
208,410,644
SC 13G/A
Feb 05, 2021
blackrock inc.
7.8%
196,213,804
SC 13G/A
Feb 12, 2020
vanguard group inc
8.26%
210,542,333
SC 13G/A
Feb 05, 2020
blackrock inc.
7.5%
190,783,225
SC 13G/A

Recent SEC filings of Merck & Co Inc

View All Filings
Date Filed Form Type Document
Feb 20, 2024
8-K
Current Report
Feb 15, 2024
4
Insider Trading
Feb 15, 2024
4
Insider Trading
Feb 14, 2024
144
Notice of Insider Sale Intent
Feb 14, 2024
144
Notice of Insider Sale Intent
Feb 14, 2024
144
Notice of Insider Sale Intent
Feb 14, 2024
4
Insider Trading
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 13, 2024
144
Notice of Insider Sale Intent
Feb 13, 2024
144
Notice of Insider Sale Intent

What is the Fair Value of MRK?

Loading...
Disclaimer: Conduct thorough research and seek guidance from a certified financial advisor prior to finalizing any investment choices.

Peers (Alternatives to Merck & Co Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
389.7B
93.0B
-3.60% -2.76%
11.09
4.19
6.46% 95.94%
156.7B
46.5B
-3.76% -37.06%
-112.85
3.37
42.59% -114.62%
155.0B
28.2B
-7.44% 18.02%
23.07
5.5
7.09% 2.52%
91.6B
27.1B
-17.13% -16.65%
16.18
3.38
-0.60% 23.36%
14.4B
15.8B
15.02% 26.90%
-25.85
0.91
6.17% 77.01%
MID-CAP
4.9B
1.7B
14.11% 18.79%
13.89
2.97
49.61% 324.78%
4.4B
4.7B
-2.94% -9.06%
-1.1K
0.94
5.74% 96.18%
3.4B
8.8B
-0.23% 18.85%
-5.66
0.38
7.79% -163.11%
2.6B
601.3M
-0.28% 70.16%
18.9
4.25
24.02% 75.17%
SMALL-CAP
1.3B
700.5M
2.67% -
-0.91
1.86
16.26% -147.49%
23.8M
70.0M
-0.88% -54.80%
0.35
0.34
-19.54% 888.31%
22.4M
84.1M
58.23% -28.98%
-1.05
0.22
2882.68% -145.15%
16.2M
111.1M
-6.33% -18.68%
-1.02
0.15
-10.43% 84.90%
2.2M
20.0M
-35.83% -91.10%
-0.16
0.11
137.71% 66.04%

Merck & Co Inc News

Latest updates
InvestorsObserver23 hours ago
Yahoo Finance20 Feb 202408:11 pm
Insider Monkey19 Feb 202404:30 pm

Merck & Co Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue6.2%15,96215,03514,48713,83014,95914,59315,90113,52113,15411,40210,62710,06410,9299,35312,0574,14912,39711,76010,81610,99810,794
  S&GA Expenses-6.8%2,5192,7022,4792,6872,5202,5122,3232,8302,3362,2812,1872,4372,0602,0852,5551,7292,5892,7122,4252,6432,443
  R&D Expenses-75.2%3,30713,3214,2763,7754,3992,7982,5763,0682,4454,3212,4125,7713,3492,0852,2092,4003,2042,1891,9312,2142,068
EBITDA Margin25.6%0.15*0.12*0.29*0.31*0.32*0.35*0.32*0.32*0.19*0.14*0.17*0.19*---------
Income Taxes36.6%87063782549633053855485.006955032387.00380396619306440615205827707
Earnings Before Taxes205.3%5,620-5,3353,6503,5133,5834,4874,8613,9095,2661,7172,987-2,9832,7062,7413,838-1,5022,3473,2593,0672,6052,665
EBT Margin35.3%0.13*0.09*0.26*0.28*0.29*0.32*0.29*0.28*0.15*0.10*0.13*0.15*---------
Net Income179.4%4,745-5,9752,8213,0173,2483,9444,3103,7584,5671,5453,179-2,0942,9413,0023,2192,3571,9012,6702,9151,8271,950
Net Income Margin45.6%0.08*0.05*0.23*0.24*0.26*0.29*0.26*0.27*0.16*0.13*0.17*0.17*---------
Free Cashflow108.3%7,7173,7041,3394,4305,6024,3024,7615,0954,7971,4391,7914,0062,1733,367707------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets2.2%106,727104,469107,796109,160107,081107,095106,668105,69493,49490,68890,84791,58889,80090,61584,91384,39783,33183,96582,35482,63785,130
  Current Assets6.6%31,95429,97733,40235,72233,56132,11631,18430,26631,05828,66526,90927,76426,57729,34326,17427,48326,14224,29825,35125,87526,836
    Cash Equivalents52.0%8,6055,6609,70712,69411,2799,7538,6148,16710,0468,6306,8828,1537,40111,1477,4609,9347,8716,6608,0777,9677,828
  Inventory3.4%6,1315,9305,8635,9115,6145,5355,7745,9535,6035,4996,4025,5546,1286,0565,8465,9785,8555,8475,7125,4405,416
  Net PPE1.3%22,52622,23121,75821,42220,42420,05919,74719,27918,56518,06418,29517,00016,91915,78915,26914,29714,28713,86213,50613,29112,755
  Goodwill-0.1%21,18321,19521,20921,20421,16021,21321,25821,26418,86218,87320,21218,88220,24823919,76718,06919,48019,4901,37618,25318,258
  Current Liabilities-1.3%23,09423,39423,13124,23922,99823,16822,31623,87223,72821,90626,36127,32720,40522,17823,48322,22020,68420,08518,54322,20618,586
  Long Term Debt-0.3%33,97234,07228,07428,74528,48228,68430,58630,69022,90724,03324,00225,36026,32126,15621,63722,73622,67722,77122,72119,80619,936
    LT Debt, Non Current-0.3%33,97234,07228,07428,74528,48228,68430,58630,69022,90724,03324,00225,36026,32126,15621,63722,73622,67722,77122,72119,80619,936
Shareholder's Equity6.5%41,24638,74246,90545,99144,52443,31840,95338,25735,86333,38827,03925,40429,27027,74426,30026,00126,92527,73727,67026,88232,656
  Retained Earnings5.3%57,08254,19862,03961,08159,92858,43756,25253,69651,69148,77748,88847,36251,10749,72448,27246,60245,80445,29544,06542,57942,189
  Additional Paid-In Capital0.3%44,35844,21944,46744,37944,24344,11544,27544,23844,14944,03939,61339,58839,48939,37339,69739,66039,56139,48438,76838,80839,762
Accumulated Depreciation0.1%18,44618,43218,25617,98517,92117,79818,49818,19218,15518,23618,73218,16218,57218,18217,70617,68617,28117,04916,62316,32416,568
Minority Interest10.2%54.0049.0071.0067.0066.0075.0070.0073.0069.0094.0094.0087.0084.0010295.0094.0087.00102131181234
Float------230,820---196,870---195,461---215,106---
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations108.3%7,7173,7041,3394,4305,6024,3024,7615,0954,7971,9901,2403,4101,5821,9187072384,2263,0841,3363,5922,793
  Share Based Compensation-3.0%16416914514513913712011911713211199.0012612110883.0010111193.0087.0091.00
Cashflow From Investing97.1%-334-11,443-2,359-1,748-962-1,077-1,173-12,049-1,061-2,625-686-4,697-2,086-782-1,628-663191-2,4253682,1781,660
Cashflow From Financing-213.6%-4,2693,758-2,054-1,554-2,702-1,777-3,0865,207-2,2742,262-2,0981,372-3,8511,137-1,490-2,011-3,152-2,084-1,614-5,566-1,905
  Dividend Payments-1.6%1,8551,8851,8531,7501,7471,7701,7451,6431,6491,6731,6451,5421,5451,5771,5511,4051,3941,4681,4281,2771,285
  Buy Backs37.9%466338149----18.00583239----1,2811,0501,4051,2351,0905,933996

MRK Income Statement

2023-09-30
CONDENSED CONSOLIDATED STATEMENT OF INCOME - USD ($)
$ in Millions
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]    
Sales$ 15,962$ 14,959$ 45,485$ 45,453
Costs, Expenses and Other    
Cost of sales4,2643,93412,21413,530
Selling, general and administrative2,5192,5207,7007,355
Research and development3,3074,39920,9049,773
Restructuring costs12694344288
Other (income) expense, net1264293881,576
Total Costs, Expenses and Other10,34211,37641,55032,522
Income Before Taxes5,6203,5833,93512,931
Taxes on Income8703302,3321,423
Net Income4,7503,2531,60311,508
Less: Net Income Attributable to Noncontrolling Interests55126
Net Income Attributable to Merck & Co., Inc.$ 4,745$ 3,248$ 1,591$ 11,502
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)$ 1.87$ 1.28$ 0.63$ 4.55
Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)$ 1.86$ 1.28$ 0.62$ 4.53

MRK Balance Sheet

2023-09-30
CONDENSED CONSOLIDATED BALANCE SHEET - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
Current Assets  
Cash and cash equivalents$ 8,605$ 12,694
Short-term investments168498
Accounts receivable (net of allowance for doubtful accounts of $85 in 2023 and $72 in 2022)10,3949,450
Inventories (excludes inventories of $3,151 in 2023 and $2,938 in 2022 classified in Other assets - see Note 7)6,1315,911
Other current assets6,6567,169
Total current assets31,95435,722
Investments1,3061,015
Property, Plant and Equipment, at cost, net of accumulated depreciation of $18,446 in 2023 and $17,985 in 202222,52621,422
Goodwill21,18321,204
Other Intangibles, Net19,19920,269
Other Assets10,5599,528
Total Assets106,727109,160
Current Liabilities  
Loans payable and current portion of long-term debt8871,946
Trade accounts payable3,5094,264
Accrued and other current liabilities14,84014,159
Income taxes payable1,9811,986
Dividends payable1,8771,884
Total current liabilities23,09424,239
Long-Term Debt33,97228,745
Deferred Income Taxes1,0181,795
Other Noncurrent Liabilities7,3438,323
Merck & Co., Inc. Stockholders’ Equity  
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2023 and 20221,7881,788
Other paid-in capital44,35844,379
Retained earnings57,08261,081
Accumulated other comprehensive loss(4,916)(4,768)
Stockholders' equity before deduction for treasury stock98,312102,480
Less treasury stock, at cost: 1,041,809,729 shares in 2023 and 1,039,269,638 shares in 202257,06656,489
Total Merck & Co., Inc. stockholders’ equity41,24645,991
Noncontrolling Interests5467
Total equity41,30046,058
Liabilities and Equity$ 106,727$ 109,160
MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
 CEO
 WEBSITEwww.merck.com
 EMPLOYEES65535

Merck & Co Inc Frequently Asked Questions


What is the ticker symbol for Merck & Co Inc? What does MRK stand for in stocks?

MRK is the stock ticker symbol of Merck & Co Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Merck & Co Inc (MRK)?

As of Fri Feb 23 2024, market cap of Merck & Co Inc is 327.98 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MRK stock?

You can check MRK's fair value in chart for subscribers.

What is the fair value of MRK stock?

You can check MRK's fair value in chart for subscribers. The fair value of Merck & Co Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Merck & Co Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MRK so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Merck & Co Inc a good stock to buy?

The fair value guage provides a quick view whether MRK is over valued or under valued. Whether Merck & Co Inc is cheap or expensive depends on the assumptions which impact Merck & Co Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MRK.

What is Merck & Co Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Feb 23 2024, MRK's PE ratio (Price to Earnings) is 71.18 and Price to Sales (PS) ratio is 5.53. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MRK PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Merck & Co Inc's stock?

In the past 10 years, Merck & Co Inc has provided 0.124 (multiply by 100 for percentage) rate of return.